Details

Autor(en) / Beteiligte

• Margalit, Ofer
• Harmsen, William S.
• Shacham-Shmueli, Einat
• Voss, Molly M.
• Boursi, Ben
• Wagner, Anna D.
• Cohen, Romain
• Olswold, Curtis L.
• Saltz, Leonard B.
• Goldstein, Daniel A.
• Hurwitz, Herbert
• Tebbutt, Niall C.
• Kabbinavar, Fairooz F.
• Adams, Richard A.
• Chibaudel, Benoist
• Grothey, Axel
• Yoshino, Takayuki
• Zalcberg, John
• de Gramont, Aimery
• Shi, Qian
• Lenz, Heinz-Josef

Titel

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Ist Teil von

• European journal of cancer (1990), 2023-01, Vol.178, p.162-170

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant. Data from 3369 patients with mCRC enrolled on four first-line randomised trials testing chemotherapy with or without bevacizumab (2000–2007) were pooled. Association between sex and progression-free survival and overall survival (OS) was evaluated by stratified Cox regression model, adjusted for potential confounders. Predictive value was evaluated by interaction effect between sex and treatment. In a pre-planned secondary analysis, analyses were stratified using an age cut point of 60 years to evaluate the possible role of menopausal-related effects. Bevacizumab was associated with an improved median OS in males and females, with a 2.3- and 0.6-months benefit, respectively. Stratified by age, bevacizumab resulted in improved OS in males at both age categories. In females at or above the age of 60 (n = 731), bevacizumab resulted in improved OS. However, in females below the age of 60 (n = 634), OS benefit did not reach statistical significance (adjusted hazard ratio = 0.94, 95% confidence interval 0.74–1.20). Our results confirmed the OS benefit from the addition of bevacizumab to first-line chemotherapy in mCRC in both sexes. Among females, the benefit was less than 1 month. For females under the age of 60, there was no survival benefit. These findings could be used to relieve financial toxicity or be redistributed within healthcare systems for other health-related purposes. •Bevacizumab was associated with an improved median overall survival (OS) of 1.8 months.•For females, median OS benefit from bevacizumab was <1 month.•For females under the age of 60, there was no OS benefit.•Sex- and age-specific reporting is essential in future trials testing bevacizumab.